L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
Von Schwab et al, erschienen in „Neurology“ (Vol. 81, Nr. 10, September 2013)
Von Schwab et al, erschienen in „Neurology“ (Vol. 81, Nr. 10, September 2013)